Endocrine Abstracts

Myasthenia gravis (MG) and Graves’ ophthalmopathy (GO) share many clinical characteristics but may also co-exist. Both are autoimmune disorders mediated by organ specific pathogenic autoantibodies to membrane surface receptors. Differential diagnosis and/or co-existence provides a potential management challenge, and there is a paucity of demographic information regarding precise prevalence rates and concurrence of disease.Method: Re...

Background: Thyroid eye disease (TED) affects 25% of patients with Graves’ disease (GD). GD affects nearly 1% of pregnancies. However, data on TED incidence, course, management and outcome in pregnancy are limited.Aims: To describe the prevalence, course and outcomes of TED in pregnant females.Methods: A retrospective analysis of electronic health records was conducted in a sp...

Generally, after an initial active phase TED rarely reactivates. However, epidemiological evidence is scant. The following cases highlight the propensity for Graves’ orbitopathy to reactivate many years later.Case 1: A 69-year-old woman had Graves’ disease aged 29, and was reviewed in the TED clinic (ophthalmology, rheumatology and endocrinology), with reactivation of orbitopathy 40 years after initial disease. She was an ex-smoker, had hyperte...